•
Mar 31
STERIS Q4 2025 Earnings Report
STERIS reported modest growth in Q4 2025 driven by strong performance in Healthcare and Applied Sterilization Technologies segments.
Key Takeaways
STERIS delivered a 4% revenue increase in Q4 2025, supported by solid gains in service and consumables, though Life Sciences saw a decline due to divestiture impacts.
Q4 revenue rose to $1.5 billion, up 4% year-over-year.
Adjusted EPS increased to $2.74 from $2.41 a year ago.
Healthcare segment showed strong service and consumables growth.
Life Sciences revenue declined due to business divestiture and reduced capital equipment sales.
STERIS
STERIS
STERIS Revenue by Segment
Forward Guidance
STERIS expects 6-7% revenue growth and up to 10% increase in adjusted EPS in FY26.
Positive Outlook
- Expected 6–7% revenue growth in FY26.
- Currency impact anticipated to be neutral.
- Adjusted EPS forecasted between $9.90 and $10.15.
- Free cash flow expected around $770 million.
- Capital expenditures planned at $375 million.
Challenges Ahead
- Tariffs expected to reduce pre-tax profit by $30 million.
- Labor and energy cost pressures persist.
- Impact of CECS divestiture on Life Sciences segment.
- Capital equipment revenue remains volatile.
- Potential headwinds from inflation and global market conditions.